Healthcare
NRx Pharmaceuticals, Inc.(NRXP)
Live Price
Offline$3.96
-0.50% today
1Y Change
+13.71%
Window
Jun 26, 2025 โ Jun 17, 2026
- Market Cap
- $50.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +43.9%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 26, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
NRx Pharmaceuticals, Inc. (NRXP) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $3.96 and up 13.7% across the available one-year price window (Jun 26, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +43.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +43.9%, free cash flow -32.7% with operating margin -1322.0% and ROIC 105.8%. Valuation already assumes a fairly strong business story at price/sales 43.6. Stock Foundry combines NRXP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-1322.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +43.9%, while operating margin sits near -1322.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +16.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | +5.2% | +44.4% | โ |
2026 Mar 23, 2026 | +1050.0% | +20.3% | +18.1% | +66.7% |
2025 Nov 14, 2025 | -63.6% | -15.3% | -14.5% | -20.5% |
Benchmark Edge
NRXP vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NRXP
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NRXP Max Drawdown
-54.22%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NRXP and SPY.
Company Overview
NRx Pharmaceuticals, Inc.
NASDAQ Global Market
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
- Leadership
- Jonathan C. Javitt
- IPO Date
- Dec 4, 2017
- Employees
- 2
- Street Address
- 1201 Orange Street
- Mailing
- Wilmington, DE, 19801
- Region
- Wilmington, DE, US
- Reporting Currency
- USD
- Investor Line
- 484 254 6134
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 43.6
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- +43.9%
- Free Cash Flow
- -32.7%
Profitability
- Gross Margin
- 50.6%
- Operating Margin
- -1322.0%
- Net Margin
- -2336.6%
- ROE
- 111.7%
- ROIC
- 105.8%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.31
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.